Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide α1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps(TM) ELISA
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide α1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps(TM) ELISA. / Fledelius, C.; Kolding, I.; Qvist, P.; Bonde, M.; Hassager, C.; Reginster, J. Y.; Hejgaard, J.; Frøkiær, H.; Christiansen, C.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 57, No. 1, 1997, p. 73-83.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide α1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps(TM) ELISA
AU - Fledelius, C.
AU - Kolding, I.
AU - Qvist, P.
AU - Bonde, M.
AU - Hassager, C.
AU - Reginster, J. Y.
AU - Hejgaard, J.
AU - Frøkiær, H.
AU - Christiansen, C.
PY - 1997
Y1 - 1997
N2 - A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide α1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 μg l-1 with a detection limit of 25 μg l-1. Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6% ± 5.3 (mean ± 1SD). Values obtained in the ELISA were highly correlated (r = 0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n = 108) and patients with Paget's disease (n = 6) increased 43% (p < 0.01) and 28-fold (p < 0.001), respectively, when compared to a premenopausal level (n = 50). A decrease in the urinary concentrations of 67% (p < 0.01) was seen after 6 months in urine samples from postmenopausal women (n = 13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n = 9). Likewise, the urinary concentrations decreased 88% (p < 0.001) in early postmenopausal women receiving bisphosphonate therapy (n = 11) for a period of 9 months compared to a group receiving placebo (n = 12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation.
AB - A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide α1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 μg l-1 with a detection limit of 25 μg l-1. Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6% ± 5.3 (mean ± 1SD). Values obtained in the ELISA were highly correlated (r = 0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n = 108) and patients with Paget's disease (n = 6) increased 43% (p < 0.01) and 28-fold (p < 0.001), respectively, when compared to a premenopausal level (n = 50). A decrease in the urinary concentrations of 67% (p < 0.01) was seen after 6 months in urine samples from postmenopausal women (n = 13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n = 9). Likewise, the urinary concentrations decreased 88% (p < 0.001) in early postmenopausal women receiving bisphosphonate therapy (n = 11) for a period of 9 months compared to a group receiving placebo (n = 12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation.
KW - Antiresorptive therapy
KW - Bone
KW - Bone resorption
KW - Hormone replacement therapy
KW - Menopause
KW - Paget's disease
KW - Type I collagen
UR - http://www.scopus.com/inward/record.url?scp=0030892865&partnerID=8YFLogxK
U2 - 10.1080/00365519709057821
DO - 10.1080/00365519709057821
M3 - Journal article
C2 - 9127460
AN - SCOPUS:0030892865
VL - 57
SP - 73
EP - 83
JO - Scandinavian Journal of Clinical and Laboratory Investigation. Supplement
JF - Scandinavian Journal of Clinical and Laboratory Investigation. Supplement
SN - 0085-591X
IS - 1
ER -
ID: 331794435